Ali Tinazli Abstract:
New imperatives of healthcare are focusing on prevention, personalization of diagnostics and treatment, and democratization, including access to everyone, anywhere, anytime at a low cost. The technology convergence in medicine is enabled by the powerful combination of microelectronics, microfluidics, distributed network and data analytics.
Bio:
Dr. Ali Tinazli is leading the corporate-wide, global strategy for Healthcare and Life Sciences for HP Inc. in the CTO Office. He currently sits on the Advisory Board of a bioinformatics/computer processor company, and serves as a Board Member at various start-up companies in the biomedical/digital health space. Dr. Ali Tinazli has a deep background in the science and business of biomedicine and healthcare. Ali has done extensive work in the field of molecular biology of aging and nanobiotechnology and has authored about 20 publications. He received his PhD in BioChemistry from J.W. Goethe University in Germany, and also studied business at UC, Berkeley’s Haas School of Business and MIT’s Sloan School of Management. After receiving his Ph.D., Ali was in Corporate Development at Applied Biosystems (now: Thermo Fisher) where he conducted technology scouting and in-licensing. From 2008-2015, Dr. Tinazli, built the biomedical consumables business at Sony DADC (part of SONY Corporation). As a member of the management team at Sony DADC BioSciences, he has headed as VP & Head of Business Development the Americas business based out of Cambridge, MA. In addition to his bioscience and industry domain experience, Ali has strong entrepreneurial experience and hands-on knowledge of the biosciences start-up community.